leadf
logo-loader
viewGeneius Biotechnology Inc

Geneius Biotechnology's T-cell therapy product in preclinical testing to treat variety of cancers

Geneius Biotechnology Inc CEO Alfred Slanetz tells Proactive Investors the company is focused on the discovery and clinical development of adoptive T- cell therapy products to treat cancer.

Slanetz says the biotech's lead product candidate is currently in preclinical testing for gastric and nasopharyngeal cancers.

Geneius is privately held but the CEO will look to take the company public by the end of 2020.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Luminex Resources CEO says stay tuned for drill results out of its Condor...

Luminex Resources Corp. (TSXV: LR) (OTCQX: LUMIF) CEO Marshall Koval tells Proactive the Vancouver-based mining company is making progress on its Condor Gold-Copper Project in Zamora-Chinchipe Province, southeast Ecuador. Koval says the group has advanced metallurgy at the site, continuing to...

2 days, 2 hours ago

2 min read